Wooseong Kim, Ph.D. - Publications

2012 Computer Science University of California, Los Angeles, Los Angeles, CA 
wireless ad hoc networks; peer to peer communications; dynamic spectrum access; wireless security; mobile health system

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Jeong S, Lee H, Kim S, Ju S, Kim W, Cho H, Kim HY, Heo G, Im E, Yoo JW, Yoon IS, Jung Y. 5-Aminosalicylic Acid Azo-coupled with a GPR109A Agonist Is a Colon-targeted Anti-colitic Codrug with a Reduced Risk of Skin Toxicity. Molecular Pharmaceutics. PMID 31743034 DOI: 10.1021/acs.molpharmaceut.9b00872  0.4
2019 Kim W, Kim D, Jeong S, Ju S, Lee H, Kim S, Yoo JW, Yoon IS, Jung Y. Conjugation of Amisulpride, an Anti-Psychotic Agent, with 5-Aminosalicylic Acid via an Azo Bond Yields an Orally Active Mutual Prodrug against Rat Colitis. Pharmaceutics. 11. PMID 31703411 DOI: 10.3390/pharmaceutics11110585  0.4
2019 Kim W, Lee H, Kim S, Joo S, Jeong S, Yoo JW, Jung Y. Sofalcone, a gastroprotective drug, covalently binds to KEAP1 to activate Nrf2 resulting in anti-colitic activity. European Journal of Pharmacology. 172722. PMID 31614142 DOI: 10.1016/j.ejphar.2019.172722  0.4
2019 Kim W, Kim S, Ju S, Lee H, Jeong S, Yoo JW, Yoon IS, Jung Y. Colon-targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anti-colitic Drug via Nrf2 activation. Molecular Pharmaceutics. PMID 31386809 DOI: 10.1021/acs.molpharmaceut.9b00664  0.4
2019 Park H, Kim W, Kim D, Jeong S, Jung Y. Mesalazine activates adenosine monophosphate-activated protein kinase: Implication in the anti-inflammatory activity of this anti-colitic drug. Current Molecular Pharmacology. PMID 30848228 DOI: 10.2174/1874467212666190308103448  0.4
2019 Yang Y, Kim W, Kim D, Jeong S, Yoo JW, Jung Y. A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model. Drug Design, Development and Therapy. 13: 231-242. PMID 30643389 DOI: 10.2147/DDDT.S185257  0.4
2018 Kim D, Kim W, Jeong S, Kim D, Yoo JW, Jung Y. Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery. Drug Delivery and Translational Research. PMID 30426357 DOI: 10.1007/s13346-018-00599-7  0.4
2018 Kim SJ, Noh TH, Son S, Kim DH, Kim W, Lee Y, Choo J, Heo G, Kim MJ, Chung HY, Jung Y, Jung JH, Moon HR, Im E. Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer. Cell Death & Disease. 9: 877. PMID 30158525 DOI: 10.1038/s41419-018-0942-x  0.4
2018 Oshi MA, Naeem M, Bae J, Kim J, Lee J, Hasan N, Kim W, Im E, Jung Y, Yoo JW. Colon-targeted dexamethasone microcrystals with pH-sensitive chitosan/alginate/Eudragit S multilayers for the treatment of inflammatory bowel disease. Carbohydrate Polymers. 198: 434-442. PMID 30093020 DOI: 10.1016/j.carbpol.2018.06.107  0.4
2017 Yum S, Jeong S, Kim D, Lee S, Kim W, Yoo JW, Kim JA, Kwon OS, Kim DD, Min DS, Jung Y. Minoxidil Induction of VEGF Is Mediated by Inhibition of HIF-Prolyl Hydroxylase. International Journal of Molecular Sciences. 19. PMID 29295567 DOI: 10.3390/ijms19010053  0.4
2017 Kim W, Yang Y, Kim D, Jeong S, Yoo JW, Yoon JH, Jung Y. Conjugation of metronidazole with dextran: a potential pharmaceutical strategy to control colonic distribution of the anti-amebic drug susceptible to metabolism by colonic microbes. Drug Design, Development and Therapy. 11: 419-429. PMID 28243064 DOI: 10.2147/DDDT.S129922  0.4
2016 Lee S, Jeong S, Kim W, Kim D, Yang Y, Yoon JH, Kim BJ, Min DS, Jung Y. Rebamipide induces the gastric mucosal protective factor, cyclooxygenase-2, via activation of 5'-AMP-activated protein kinase. Biochemical and Biophysical Research Communications. PMID 28011266 DOI: 10.1016/j.bbrc.2016.12.123  0.4
2016 Kim W, Nam J, Lee S, Jeong S, Jung Y. 5-Aminosalicylic acid azo-linked to procainamide acts as an anti-colitic mutual prodrug via additive inhibition of nuclear factor kappaB. Molecular Pharmaceutics. PMID 27112518 DOI: 10.1021/acs.molpharmaceut.6b00294  0.4
2016 Kim WJ, Kwon CH, Han S, Lee WS, Kang JW, Ahn JM, Lee JY, Park DW, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park SJ. Role of coronary artery calcium scoring in detection of coronary artery disease according to framingham risk score in populations with low to intermediate risks Journal of Korean Medical Science. 31: 902-908. DOI: 10.3346/jkms.2016.31.6.902  0.4
2015 Kim JH, Kim WS, Ryu K, Kim SJ, Park C. CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Leukemia & Lymphoma. 1-10. PMID 26699656 DOI: 10.3109/10428194.2015.1113276  0.32
2015 Nam J, Kim W, Lee S, Jeong S, Yoo JW, Kim MS, Jung Y. Dextran-5-(4-ethoxycarbonylphenylazo)salicylic acid ester, a polymeric colon-specific prodrug releasing 5-aminosalicylic acid and benzocaine, ameliorates TNBS-induced rat colitis. Journal of Drug Targeting. 1-7. PMID 26377354 DOI: 10.3109/1061186X.2015.1087528  0.4
2015 Lee S, Lee Y, Kim W, Nam J, Jeong S, Yoo JW, Kim MS, Moon HR, Jung Y. Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target. Drug Design, Development and Therapy. 9: 4227-37. PMID 26300626 DOI: 10.2147/DDDT.S88543  0.4
2015 Yum S, Jeong S, Lee S, Nam J, Kim W, Yoo JW, Kim MS, Lee BL, Jung Y. Colon-targeted delivery of piceatannol enhances anti-colitic effects of the natural product: potential molecular mechanisms for therapeutic enhancement. Drug Design, Development and Therapy. 9: 4247-58. PMID 26273188 DOI: 10.2147/DDDT.S88670  0.4
2015 Lee Y, Kim J, Kim W, Nam J, Jeong S, Lee S, Yoo JW, Kim MS, Jung Y. Celecoxib coupled to dextran via a glutamic acid linker yields a polymeric prodrug suitable for colonic delivery. Drug Design, Development and Therapy. 9: 4105-13. PMID 26251576 DOI: 10.2147/DDDT.S89077  0.4
2015 Kim W, Lee Y, Jeong S, Nam J, Lee S, Jung Y. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent. Archives of Pharmacal Research. PMID 25860026 DOI: 10.1007/s12272-015-0602-y  0.4
2015 Yum S, Jeong S, Lee S, Kim W, Nam J, Jung Y. HIF-prolyl hydroxylase is a potential molecular target for esculetin-mediated anti-colitic effects. Fitoterapia. 103: 55-62. PMID 25797536 DOI: 10.1016/j.fitote.2015.03.013  0.4
2015 Jeong S, Park H, Hong S, Yum S, Kim W, Jung Y. Lipophilic modification enhances anti-colitic properties of rosmarinic acid by potentiating its HIF-prolyl hydroxylases inhibitory activity. European Journal of Pharmacology. 747: 114-22. PMID 25483211 DOI: 10.1016/j.ejphar.2014.11.030  0.4
2015 Naeem M, Cao J, Choi M, Kim WS, Moon HR, Lee BL, Kim MS, Jung Y, Yoo JW. Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles International Journal of Nanomedicine. 10: 4565-4580. DOI: 10.2147/IJN.S87816  0.4
2014 Han S, Huh J, Kim W, Jeong S, Min do S, Jung Y. Phospholipase D activates HIF-1-VEGF pathway via phosphatidic acid. Experimental & Molecular Medicine. 46: e126. PMID 25523098 DOI: 10.1038/emm.2014.86  0.4
2014 Naeem M, Kim W, Cao J, Jung Y, Yoo JW. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug delivery to the inflamed colon. Colloids and Surfaces. B, Biointerfaces. 123: 271-8. PMID 25266978 DOI: 10.1016/j.colsurfb.2014.09.026  0.4
2014 Lee Y, Kim W, Hong S, Park H, Yum S, Yoon JH, Jung Y. Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages. European Journal of Pharmacology. 726: 49-56. PMID 24462351 DOI: 10.1016/j.ejphar.2014.01.011  0.4
2014 Yum S, Park H, Hong S, Jeong S, Kim W, Jung Y. N-(2-Mercaptopropionyl)-glycine, a diffusible antioxidant, activates HIF-1 by inhibiting HIF prolyl hydroxylase-2: implication in amelioration of rat colitis by the antioxidant. Biochemical and Biophysical Research Communications. 443: 1008-13. PMID 24361888 DOI: 10.1016/j.bbrc.2013.12.081  0.4
2014 Kim YT, Yum S, Heo JS, Kim W, Jung Y, Kim YM. Dithiocarbamate chitosan as a potential polymeric matrix for controlled drug release. Drug Development and Industrial Pharmacy. 40: 192-200. PMID 23323844 DOI: 10.3109/03639045.2012.753900  0.4
2013 Kim H, Kim W, Yum S, Hong S, Oh JE, Lee JW, Kwak MK, Park EJ, Na DH, Jung Y. Caffeic acid phenethyl ester activation of Nrf2 pathway is enhanced under oxidative state: structural analysis and potential as a pathologically targeted therapeutic agent in treatment of colonic inflammation. Free Radical Biology & Medicine. 65: 552-62. PMID 23892357 DOI: 10.1016/j.freeradbiomed.2013.07.015  0.4
2013 Lee Y, Jeong S, Kim W, Kim H, Yoon JH, Jeong SH, Jung Y. Glycyrrhizin enhances therapeutic activity of a colon-specific methylprednisolone prodrug against experimental colitis. Digestive Diseases and Sciences. 58: 1226-34. PMID 23192646 DOI: 10.1007/s10620-012-2495-7  0.4
2012 Lee Y, Kim H, Kim W, Yoon JH, Jeong SH, Jung Y. Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis. Journal of Drug Targeting. 20: 524-34. PMID 22632102 DOI: 10.3109/1061186X.2012.693498  0.4
Show low-probability matches.